Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
ESMO 2022 eBook
The European Society of Medical Oncology Conference (ESMO) in Paris has wrapped up and there was much to talk about as Europe’s top oncologists came together to announce their breakthroughs, disappointments and everything inbetween. As always, the Evaluate Vantage team stayed on top of all the announcements to report back on the key highlights and…
Report library
Medtech World Preview 2022: Back to Reality Report
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. Huge demand for Covid…
Medtech World Preview 2022: Back to Reality Infographic
Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. As the pandemic…
PD(L)anner – September 2022
Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been…
Medtech Infographic: The only way is up - or is it?
As we venture into the second half of 2022, has the medtech market hit its lowest ebb? Will the slump continue or are there a few flickers of light on the horizon, if you…
Pharma Infographic: The only way is up - or is it?
In a world awash with information, Evaluate is here to provide clarity with best-in-class data and expert insight. As we come to the end of a very rocky first…
Biopharma, Biotech and Medtech in Q2: The only way is up or is it?
The first half of 2022 is behind us and for most in the industry, it was a six month period to forget. Have we hit the bottom, or will we plummet still further in the…
Access Valuable Insights Payer Behaviour Infographic
During early-stage development, it has become more critical than ever to factor in payer perspectives and reimbursement dynamics. For a clearer understanding of the payer…
Medtech - Going steady
The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including…
Pharma Drivers eBook 1: Hey Big (Pharma) Spender
Big pharma spent £183bn on R&D, M&A and licensing deals in 2021. Huge though that figure is, it’s actually a slight dip in overall spend compared to the previous…
Pharma Drivers Ebook Part 2: Ch-ch-changes
2028-2029 will see some of the biggest blockbusters on the market lose their exclusivity with up to $115bn of sales at risk across those two years. Realistically, of…
